13G Filing: Opaleye Management and Inotek Pharmaceuticals Corp (ITEK)

SIGNATURE

 

After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.

 

Date: October 6, 2017	By:	/s/ James Silverman
		James Silverman
	Opaleye, L.P.
Date: October 6, 2017	By:	/s/ James Silverman
	Name:	James Silverman
	Title:	Managing Member of Opaleye
		GP LLC, the General Partner of
		Opaleye, L.P.
	Opaleye Management Inc.
Date: October 6, 2017	By:	/s/ James Silverman
	Name:	James Silverman
	Title:	President

 

JOINT
FILING AGREEMENT

 

This
Joint Filing Agreement, dated October 6, 2017, is entered into by and between Opaleye Management Inc., a Massachusetts corporation,
Opaleye, L.P., a Delaware limited partnership and James Silverman, an individual (collectively referred to herein as (the “Filers”).
Each of the Filers may be required to file with the U.S. Securities and Exchange Commission a statement on Schedule 13G with respect
to common stock, $0.001 par value, of Inotek Pharmaceuticals Corporation beneficially owned by them from time to time. Pursuant
to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby
agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and
hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint
Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice
as the Filers may mutually agree.

 

DATED:
October 6, 2017

 

	By:	/s/ James Silverman
		James Silverman
	Opaleye, L.P.
	By:	/s/ James Silverman
	Name:	James Silverman
	Title:	Managing Member of
		Opaleye GP LLC, the General Partner
		of Opaleye, L.P.
	Opaleye Management Inc.
	By:	/s/ James Silverman
	Name:	James Silverman
	Title:	President